Patents by Inventor Samuel Zalipsky

Samuel Zalipsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10722591
    Abstract: The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker. The present disclosure also related to methods for preparation of the cleavable conjugates, uses thereof for stimulating an effective immune response, and uses thereof for the treatment of cancer.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: July 28, 2020
    Assignee: Dynavax Technologies Corporation
    Inventors: Robert L. Coffman, Stewart D. Chipman, Radwan Kiwan, Samuel Zalipsky, Gary S. Ott
  • Publication number: 20190151462
    Abstract: The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker. The present disclosure also related to methods for preparation of the cleavable conjugates, uses thereof for stimulating an effective immune response, and uses thereof for the treatment of cancer.
    Type: Application
    Filed: November 13, 2018
    Publication date: May 23, 2019
    Applicant: Dynavax Technologies Corporation
    Inventors: Robert L. COFFMAN, Stewart D. CHIPMAN, Radwan KIWAN, Samuel ZALIPSKY, Gary S. OTT
  • Patent number: 9259350
    Abstract: Contact lenses comprising phosphorylcholine groups release beneficial polyionic or guanidinium-containing agents.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: February 16, 2016
    Assignee: CooperVision International Holding Company, LP
    Inventors: Victoria Rogers, Andrew Luk, Arthur Back, Samuel Zalipsky
  • Publication number: 20150374542
    Abstract: Contact lenses comprising phosphorylcholine groups release beneficial polyionic or guanidinium-containing agents.
    Type: Application
    Filed: September 9, 2015
    Publication date: December 31, 2015
    Applicant: CooperVision International Holding Company, LP
    Inventors: Victoria Rogers, Andrew Luk, Arthur Back, Samuel Zalipsky
  • Patent number: 9161598
    Abstract: Contact lenses comprising phosphorylcholine groups release beneficial polyionic or guanidinium-containing agents.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: October 20, 2015
    Assignee: CooperVision International Holding Company, LP
    Inventors: Victoria Rogers, Andrew Luk, Arthur Back, Samuel Zalipsky
  • Publication number: 20140174957
    Abstract: Contact lenses comprising phosphorylcholine groups release beneficial polyionic or guanidinium-containing agents.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 26, 2014
    Applicant: CooperVision International Holding Company, LP
    Inventors: Victoria Rogers, Andrew Luk, Arthur Back, Samuel Zalipsky
  • Publication number: 20110282093
    Abstract: The invention relates to heterobifunctional polyethylene glycol reagents, methods of producing them and methods of using them.
    Type: Application
    Filed: November 12, 2008
    Publication date: November 17, 2011
    Applicant: Intradigm Corporation
    Inventors: Daniel E. Levy, Samuel Zalipsky, Steven M. Chamow
  • Publication number: 20090306349
    Abstract: A method for conjugation of glycosylated Fc-containing proteins is described. The method comprises carbamate chemistry performed and neutral pH or below and the resulting Fc-containing protein are expected to retain tertiary structure and therefore Fc-related bioactivity such as FcR binding, the ability to bind Clq, in addition to retaining ligand binding capabilities related to the incorporation of a ligand binding peptide or other polypeptide which has binding specificity. The method is exemplified using an erythropoietin-mimetic peptide fused to a human IgG1 antibody constant domain comprising a hinge, CH2 and CH3.
    Type: Application
    Filed: March 30, 2007
    Publication date: December 10, 2009
    Inventors: Maria U. Hutchins, Samuel Zalipsky, Bernard J. Scallon
  • Patent number: 7608687
    Abstract: A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: October 27, 2009
    Assignee: Alza Corporation
    Inventor: Samuel Zalipsky
  • Patent number: 7592307
    Abstract: A conjugate comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-, hydroxy- or carboxyl-containing ligand is described. The resulting conjugate is capable of releasing the parent amine, hydroxy, or carboxyl-containing compound via thiol-mediated cleavage. The system allows for delivery of various amino-, hydroxy-, or carboxy-containing drugs in the form of their thiolytically cleavable macromolecular conjugates.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: September 22, 2009
    Assignee: Alza Corporation
    Inventors: Samuel Zalipsky, Radwan Kiwan
  • Patent number: 7476725
    Abstract: Polymer-biomolecule conjugates are prepared, generally in a site-specific or -selective manner, by a four-component condensation reaction. The method may be used to prepare conjugates having two polymer molecules attached at a single site on a biomolecule. The conjugates are typically water soluble and have beneficial pharmacological properties, such as reduced immunogenicity and increased circulation time.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: January 13, 2009
    Assignee: Alza Corporation
    Inventor: Samuel Zalipsky
  • Publication number: 20080279922
    Abstract: A conjugate comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-, hydroxy- or carboxyl-containing ligand is described. The resulting conjugate is capable of releasing the parent amine, hydroxy, or carboxyl-containing compound via thiol-mediated cleavage. The system allows for delivery of various amino-, hydroxy-, or carboxy-containing drugs in the form of their thiolytically cleavable macromolecular conjugates.
    Type: Application
    Filed: June 6, 2007
    Publication date: November 13, 2008
    Inventors: Samuel Zalipsky, Radwan Kiwan
  • Publication number: 20080152702
    Abstract: A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
    Type: Application
    Filed: September 19, 2007
    Publication date: June 26, 2008
    Inventor: Samuel Zalipsky
  • Patent number: 7390780
    Abstract: A liposome composition and method for delivery of a nucleic acid in vivo or ex vivo is described. The liposomes in the composition are comprised of (i) a cationic lipid and (ii) a lipid joined to a hydrophilic polymer by a releasable linkage. The liposomes are associated with a nucleic acid for delivery to a cell.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: June 24, 2008
    Assignee: Alza Corporation
    Inventors: Shi-Kun Huang, Samuel Zalipsky
  • Patent number: 7303760
    Abstract: Methods for administering mitomycin C to a multi-drug resistant cell and for reducing the toxicity of the compound are described. In the methods, mitoymic C is provided in the form of a prodrug conjugate, where the drug is linked to a hydrophobic moiety, such as a lipid, through a cleavable dithiobenzyl linkage. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of mitomycin C in its original form. The linkage is stable under nonreducing conditions. The prodrug conjugate can be incorporated into liposomes for administration in vivo and release of mitomycin C in response to endogenous in vivo reducing conditions or in response to administration of an exogenous reducing agent.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: December 4, 2007
    Assignees: Alza Corporation, Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Samuel Zalipsky, Alberto Gabizon
  • Patent number: 7285622
    Abstract: A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: October 23, 2007
    Assignee: Alza Corporation
    Inventor: Samuel Zalipsky
  • Patent number: 7276248
    Abstract: Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the therapeutic agent in its original form. The linkage is stable under nonreducing conditions. The conjugate can be incorporated into liposomes for administration in vivo and release of the therapeutic agent in response to endogeneous in vivo reducing conditions or in response to administration of an exogeneous reducing agent.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: October 2, 2007
    Assignee: ALZA Corporation
    Inventors: Samuel Zalipsky, Alberto A. Gabizon
  • Patent number: 7238368
    Abstract: A conjugate comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-, hydroxy- or carboxyl-containing ligand is described. The resulting conjugate is capable of releasing the parent amine, hydroxy, or carboxyl-containing compound via thiol-mediated cleavage. The system allows for delivery of various amino-, hydroxy-, or carboxy-containing drugs in the form of their thiolytically cleavable macromolecular conjugates.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: July 3, 2007
    Assignee: ALZA Corporation
    Inventors: Samuel Zalipsky, Radwan Kiwan
  • Publication number: 20070087047
    Abstract: A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.
    Type: Application
    Filed: December 1, 2006
    Publication date: April 19, 2007
    Inventors: Samuel Zalipsky, Martin Woodle, Francis Martin, Yechezkel Barenholz, Herve Bercovier
  • Publication number: 20070015701
    Abstract: A modified bone morphogenetic protein (BMP, also referred to as bone morphogenic protein) composition is described. The bone morphogenetic protein, in one embodiment, is BMP-7 which is chemically modified with a hydrophilic polymer, such as poly(ethylene glycol).
    Type: Application
    Filed: May 31, 2006
    Publication date: January 18, 2007
    Inventors: Samuel Zalipsky, Francis Farrell, Beth Hill, Radwan Kiwan